4.7 Article

Artesunate and dihydroartemisinin-piperaquine treatment failure in a severe Plasmodium falciparum malaria case imported from Republic of C?te d?Ivoire

期刊

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 122, 期 -, 页码 352-355

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2022.06.009

关键词

Malaria; Infectious disease; Drug resistance; Genotyping; Treatment failure

向作者/读者索取更多资源

A traveler returning from Ivory Coast was diagnosed with severe malaria and experienced treatment failure with two different antimalarial drugs. Molecular analysis revealed the same strain of the parasite causing the initial infection, suggesting a resurgence of the previous infection. This highlights the importance of monitoring imported malaria cases for drug resistance.
A 68-year-old man returning from Republic of Cote d'Ivoire (Ivory Coast) was diagnosed with severe Plasmodium falciparum malaria and treated with intravenous artesunate followed by oral dihydroartemisininpiperaquine (DHA-PPQ). A month later the patient experienced a new P. falciparum episode; analysis of pfmsp-1 and pfmsp-2 revealed that the infection was caused by a genetic strain identical to the strain that caused the initial episode, indicating resurgence of the previous infection. No mutations in genes associated with resistance to artemisinin derivatives ( pfk13 ) or piperaquine ( pfexonuclease, pfplasmepsin 2/3 ) were detected, suggesting that treatment failure could have been caused by drug malabsorption or poor drug manufacturing practices. A second treatment with atovaquone-proguanil was successful in eliminating the infection, with no further relapses. To our knowledge, this is the first description of a treatment failure with both artesunate and DHA-PPQ in a traveler returning from a malaria-endemic region. Analysis of molecular markers of resistance to antimalarial drugs revealed mutations associated with resistance to sulfadoxine ( pfdhps ) and pyrimethamine (pfdhfr) , highlighting the important contribution of surveillance of imported malaria cases to the monitoring of drug resistance globally.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据